Navigation Links
Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores
Date:6/2/2008

Study Published in the Journal of Clinical Oncology Proves Accurate Measurement of ER and PR Status Using Quantitative Reverse-Transcriptase

Polymerase Chain Reaction (RT-PCR)

REDWOOD CITY, Calif., June 2 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology (JCO) published results of a study confirming RT-PCR by Oncotype DX can deliver quantitative gene expression levels for assessing estrogen receptor (ER) and progesterone receptor (PR) status, which are critical factors in determining the use and benefit of hormonal therapy for the treatment of breast cancer. Based on these results, Genomic Health is now providing quantitative ER and PR scores to physicians and patients in addition to the Recurrence Score(TM) result provided in the Oncotype DX(R) report.

Unlike traditional methodologies that provide either a positive or negative result, or a semi-quantitative result, RT-PCR by Oncotype DX generates a specific score across a continuous range of expression which allows physicians to factor the quantitative level of ER and PR gene expression into their treatment planning.

"Every breast tumor expresses the estrogen receptor gene at a specific level and, similar to other diagnostic measures, the ability to more accurately pinpoint that level increases the confidence in a diagnosis and treatment plan," said Sandra Swain, M.D., Medical Director, Washington Cancer Institute, Washington Hospital Center. "Having quantitative ER and PR scores provides added certainty in confirming expression levels of these important genes in predicting how likely a patient is to benefit from hormonal therapy."

This study published in JCO was originally presented at the American Society of Clinical Oncology Breast Cancer Symposium in September 2007. It measured ER and PR gene expression in 776 breast cancer patients by both local laboratory and central immunohistochemistry (IHC), and quantitative RT-PCR, as performed by the Oncotype DX assay. Results showed a high degree of agreement between the two methods. In an accompanying editorial, Dr. Craig Allred comments, "RT-PCR is at least equivalent to IHC in its ability to identify receptor-positive cases (considering ER and PR combined), marginally superior in predicting outcome in ER-positive patients, and superior in technical precision."

"We believe the methodology of the future is the quantitative measure of the biology of each individual tumor," said Steven Shak, M.D., chief medical officer of Genomic Health. "Providing physicians with quantitative ER and PR scores enhances the value of Oncotype DX by providing more patient-specific information to help individualize treatment decisions for breast cancer patients. We are continuing to conduct additional studies, including studying the use of RT-PCR by Oncotype DX to quantify HER-2 gene expression, another cancer-related gene that plays an important role in the determination of optimal treatment for breast cancer patients."

About Oncotype DX(R)

Oncotype DX is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 55,000 tests, and health plans covering over 80 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood chemotherapy benefit as well as recurrence in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's belief that the quantitative measurement of individual tumor biology is the methodology of the future and the belief that providing quantitative ER and PR scores enhances the value of Oncotype DX. These risks and uncertainties include, but are not limited to: the results of additional clinical studies; the risk that we may not obtain sufficient levels of reimbursement for any future tests we may develop; our ability to develop and commercialize new products; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to obtain capital when needed; our history of operating losses and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the three-month period ended March 31, 2008. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
2. New insights into cellular reprogramming revealed by genomic analysis
3. /C O R R E C T I O N -- Rosetta Genomics Ltd/
4. Rosetta Genomics Reports First Quarter 2008 Financial Results
5. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
6. Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training
7. Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
8. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
9. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
10. Genomic Health to Announce First Quarter 2008 Financial Results and Host Conference Call on Tuesday, May 6, 2008
11. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):